​

Current Research Interests

​

​

Cracking the cancer code to make them more target-able to CD8+ T cells involves overcoming low antigenicity and immuno-suppression. Various formats of T cell engagers are designed to attract the cytotoxic CD8+ T cells toward the fortified cancer cell surface. Reigniting antigenicity and rediscovering missed antigens are now augmented with advances in bioengineering and assay design. I have recently developed the EZ MHC-I discovery engine to reveal MHC-I peptides that are difficult to predict. With new starting points, relevant T cell receptors can now be discovered to be developed into novel therapeutics coupled with helper cytokines.

​

​

​

Structural Immunology and Glycoimmunology

Lung Cancers in Asia

Unpredictable Neoantigen Discovery

Innovative Business Development

​